EWA
ACTU

EverSource Wealth Advisors’s Actuate Therapeutics ACTU Stock Holding History

EverSource Wealth Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406 Buy
265
+230
+657% +$533 ﹤0.01% 4164
2026
Q1 		$95 Buy
35
+33
+1,650% +$137 ﹤0.01% 4278
2025
Q4 		$12 Sell
2
-68
-97% -$467 ﹤0.01% 4246
2025
Q3 		$469 Buy
+70
New +$507 ﹤0.01% 3966

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

EverSource Wealth Advisors's ACTU Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Actuate Therapeutics (ACTU) stake by 657% in Q2 2026, buying an estimated $533 and bringing the position to 265 shares worth $406. The position accounts for ﹤0.01% of the portfolio, ranked #4164.

EverSource Wealth Advisors first reported a position in ACTU in Q3 2025 and has held it in 4 quarters since. The position peaked at $469 in Q3 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • EverSource Wealth Advisors held 265 shares of Actuate Therapeutics worth $406 as of Q2 2026.
  • EverSource Wealth Advisors bought 230 Actuate Therapeutics shares in Q2 2026, an estimated $533.
  • Actuate Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4164 holding.
  • EverSource Wealth Advisors first reported a position in Actuate Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • EverSource Wealth Advisors's Actuate Therapeutics position peaked at $469 in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.